600222.SH
Henan Taloph Pharmaceutical Stock Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 6.55
+2.34%Year over year
Reported trailing growth
- Revenue
- +1.1%
- EBITDA
- —
- EBIT
- +261.5%
- EPS
- +99.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.6%
- EBITDA
- +15.8%
- EBIT
- +32.6%
- Net income
- +17.4%
- EPS
- +18.4%
- Free cash flow
- +556.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026